United States · Bill · HR
H.R. 985 (116th)
FAST Generics Act of 2019
Introduced
5 February 2019
Last action
—
Status
Referred to the House Committee on Energy and Commerce.
Sponsors
—
Subjects
Discovery layer
Source updated
3 January 2025
Summary
Fair Access for Safe and Timely Generics Act of 2019 or the FAST Generics Act of 2019 This bill generally prohibits the license holder of a drug or biological product approved by the Food and Drug Administration from restricting availability of the drug or product for testing by a product developer seeking to develop a drug, generic drug, or biosimilar.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 5 February 2019
Introduced in House (PDF)
Introduced in House · EN · 5 February 2019
Introduced in House
summary · EN · 5 February 2019
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/house-bill/985
- Open data entity: https://api.congress.gov/v3/bill/116/hr/985